Moderna's mFLUSIVA Approval Validates mRNA Platform Beyond COVID-19: What It Means for Biopharmaceutical Manufacturing

The FDA has approved mFLUSIVA (mRNA-1010), a messenger RNA-based influenza vaccine developed by Moderna, for adults 50 years and older. The regulatory action extends mRNA platform technology into a new indication, with implications that reach well beyond the flu vaccine market.

"The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform," said Stéphane Bancel, chief executive officer of Moderna. "This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation."¹

mFLUSIVA becomes Moderna's fifth globally approved product and fourth to receive FDA clearance, alongside Spikevax, mRESVIA and mNEXSPIKE. The company’s portfolio that now spans four distinct indications built on a single delivery infrastructure. Moderna expects to have supply available at select U.S. retailers ahead of the 2026–2027 respiratory virus season.

How Does mRNA Technology Differ From Traditional Influenza Vaccine Manufacturing?

Conventional seasonal influenza vaccines are produced primarily through egg-based or cell culture processes, both of which require months of lead time to grow, harvest, purify and formulate antigen. The mRNA approach eliminates the need for biological production of protein antigens, instead encoding the genetic instructions for hemagglutinin—the surface protein targeted by flu vaccines—into lipid nanoparticle-encapsulated messenger RNA. Once injected, host cells translate those instructions directly into antigen.

This architecture offers a meaningful manufacturing flexibility advantage: strain updates require sequence changes to the mRNA construct rather than procurement and reformulation of new biological seed stocks. That speed advantage was demonstrated during the COVID-19 pandemic and is now being applied to a pathogen where antigenic drift routinely outpaces the egg-based production calendar.

Whether this translates to a durable manufacturing competitive edge at commercial scale, particularly given cold chain requirements for lipid nanoparticle formulations, remains an active area of operational planning for Moderna and its contract manufacturing network.

What Were the Clinical and Regulatory Findings That Supported Approval?

The FDA's approval for adults 50 through 64 years is based on a Phase 3 randomized, observer-blind, active-controlled trial (NCT06602024) enrolling 40,805 adults across 11 countries. The primary endpoints were safety and relative vaccine efficacy against reverse transcription polymerase chain reaction-confirmed influenza-like illness caused by any influenza A or B strain, benchmarked against a licensed standard-dose comparator.

mFLUSIVA demonstrated a relative vaccine efficacy of 26.6% (95% CI: 16.7%, 35.4%) versus standard-dose, meeting the study's pre-specified superiority criterion.¹ In the 65-and-older subgroup, relative vaccine efficacy reached 27.4%. Solicited adverse reactions of injection site pain, fatigue, headache and myalgia were predominantly mild to moderate and resolved within one to two days, with no new safety signals identified.

Approval for adults 65 and older was granted under the FDA's accelerated approval pathway, based on immunogenicity data from a separate trial (NCT05827978) enrolling 2,992 adults comparing mFLUSIVA against a high-dose inactivated influenza vaccine.² A confirmatory postmarketing trial is required to verify clinical benefit in that population, which is an important regulatory obligation given that adults 65 and older represent the highest-burden demographic for influenza-related hospitalization and death.³

What Does mFLUSIVA's Approval Signal for the Future of mRNA-Based Biologics?

From a platform perspective, each new mRNA-based approval adds to a body of regulatory precedent for lipid nanoparticle delivery, manufacturing process validation, and clinical development methodology that can inform subsequent programs in infectious disease, oncology, rare disease, and beyond.

Regulatory submissions for mFLUSIVA have been accepted for review in the European Union, Canada and Australia, with additional country submissions planned during 2026. The global rollout will test the scalability of Moderna's manufacturing network and cold chain infrastructure across regulatory jurisdictions with varying requirements for process comparability and technology transfer.

The FDA Vaccines and Related Biological Products Advisory Committee unanimously recommended mFLUSIVA for adults 50 and older prior to approval, affirming the benefit-risk assessment that has underpinned prior mRNA vaccine reviews.⁴ For biopharmaceutical developers watching this space, the precedent suggests regulators are increasingly comfortable with mRNA construct updates and formulation data packages as a basis for strain or target changes. This represents a potentially significant regulatory efficiency for future iterations of platform-derived vaccines.

Limitations to monitor include the accelerated approval status in adults 65 and older, reactogenicity rates that were modestly higher than conventional comparators, and the operational demands of lipid nanoparticle cold chain management at population-level distribution volumes.

Sources

1. mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years. Open Forum Infect Dis. 2025.

2. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine. 2025.

3. Mertz D, et al. High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review. Vaccines (Basel). 2023;11(2):439.

4. FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review. AJMC. 2026.